In the most recent examine, a team led by Imperial’s Centre for copyright Analysis analysed fMRI scans of contributors from both of these trials, which provided almost 60 individuals: an open label demo in treatment-resistant depression – where all contributors acquired psilocybin; in addition to a randomised control demo in additional basic de